skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.10e (Release date: 2017-10-30)
SearchBox Top
SearchBox Bottom
Lintuzumab (Code C1716)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Lintuzumab

Definition: A humanized recombinant monoclonal antibody directed against CD33, a cell surface antigen found on myeloid leukemia blasts and early hematopoietic progenitor cells. Lintuzumab stimulates antibody-dependent cell-mediated cytotoxicity (ADCC) against tumor cells expressing CD33, resulting in a decrease in tumor burden. The humanized version of this monoclonal antibody exhibits less immunogenicity and improved binding affinity compared to its murine counterpart.

NCI-GLOSS Definition: A substance being studied in the treatment of myelodysplastic syndromes and some types of leukemia. It binds to CD33, a protein on the surface of certain normal blood stem cells and some abnormal blood cells. It causes the immune system to kill these cells. Lintuzumab is a type of monoclonal antibody.

Display Name: Lintuzumab

Label: Lintuzumab

NCI Thesaurus Code: C1716 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0530093  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Hu-M195 monoclonal antibody
HuG1-M195 monoclonal antibody
MoAb HuG1-M195
MoAb HuM195
Monoclonal Antibody HuG1-M195
Monoclonal Antibody HuM195
monoclonal antibody HuM195 HuG1-M195

External Source Codes: 
PDQ Closed Trial Search ID 42049
PDQ Open Trial Search ID 42049 (check for NCI PDQ open clinical trial info)
UMLS CUI C0530093

Other Properties:
     Name Value (qualifiers indented underneath)
code C1716
Contributing_Source CTRP
Legacy_Concept_Name Monoclonal_Antibody_HuG1-M195
Semantic_Type Amino Acid, Peptide, or Protein
Semantic_Type Immunologic Factor

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom